Press Releases Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None2026202520242023202220212020 February 2, 2021 Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors February 2, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 7, 2020 Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer December 3, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 24, 2020 Protara Therapeutics to Present at Upcoming Virtual Investor Conferences November 12, 2020 Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview November 11, 2020 Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference November 4, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 22, 2020 Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock September 21, 2020 Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock September 8, 2020 Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications September 2, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « Previous page ‹ … Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Current page 10 Page 11 Next page › Last page » Displaying 109 - 120 of 132 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None2026202520242023202220212020 February 2, 2021 Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors February 2, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 7, 2020 Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer December 3, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 24, 2020 Protara Therapeutics to Present at Upcoming Virtual Investor Conferences November 12, 2020 Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview November 11, 2020 Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference November 4, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 22, 2020 Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock September 21, 2020 Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock September 8, 2020 Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications September 2, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « Previous page ‹ … Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Current page 10 Page 11 Next page › Last page » Displaying 109 - 120 of 132
February 2, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 7, 2020 Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer
December 3, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 12, 2020 Protara Therapeutics Announces Third Quarter 2020 Financial Results and Business Overview
November 11, 2020 Protara Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
November 4, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 22, 2020 Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
September 21, 2020 Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
September 8, 2020 Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications
September 2, 2020 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
